One study conducted a genome-wide CRISPR-Cas9 screening on IgH—CRLF2-r ALL cell lines in the presence or absence of ruxolitinib, discovering that RAS mutations and/or mTORC1 signaling activation render cells insensitive to ruxolitinib [98]. Here, CRLF2 is linked to acute lymphoblastic leukemia.